Previous 10 | Next 10 |
Summary There are many types of investors. Here are three very famous but very different types of investors. Who do you identify with the most? Which investment strategy aligns with your very own? Who do you think is going to come ahead in 2023, as well as over the next 3, 5, and 10...
Investing in cancer-fighting treatments and testing can make for a solid long-term strategy. Cancer, unfortunately, remains a big challenge for the healthcare industry, and detecting it in its early stages can play a key part in helping patients beat the prognosis. Exact Sciences (NASDA...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Biophytis (NASDAQ: BPTS ) stock is taking off on Thursday after the company released results from a Phase 2/3 clinical trial . That clinical trial covers the use of Sarconeos as a treatment f...
Last year, shares of molecular diagnostics company Exact Sciences (NASDAQ: EXAS) dropped by about 40%. However, 2023 is proving to be very different, at least so far. Exact Sciences is up by 32% since the year started. There is no question that's an impressive performance, but it hardly c...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips In November 2021, Cathie Wood described artificial intelligence as the “next big frontier” of the tech sector. Roughly a year later, OpenAI released advanced chatbot ChatGPT, and almost overnight, the ways inv...
Exact Sciences schedules fourth quarter 2022 earnings call PR Newswire MADISON, Wis. , Feb. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to re...
Summary BNGO reported preliminary Q4 results, showing acceptable core business performance. Aggressive expansion into capital-intensive markets could put significant pressure on BNGO's balance sheet. Recently-introduced LDTs will likely have a limited impact on revenue growth. ...
Summary ARK Invest’s 13F portfolio value decreased from $14.35B to $11.54B this quarter. They increased Tesla, Ginkgo Bioworks, and Coinbase Global stakes while decreasing NVIDIA, Fate Therapeutics, and TuSimple Holdings during the quarter. The top three positions are Exact S...
Cathie Wood seems to be having a fantastic start to the new year with her ARK Innovation ETF now up 25% year-to-date – and she’s continuing to make adjustments to her holdings in hopes of even better returns moving forward. Cathie Wood sells more of EXAS The billionaire inve...
Cathie Wood unloaded just over 100K shares of Exact Sciences ( NASDAQ: EXAS ) on Tuesday a few weeks after her team predicted that the stock could nearly triple in value by the year 2027. Since that call, EXAS has climbed more than 35%. In total, Wood sold 100,326 shares of EXAS throu...
News, Short Squeeze, Breakout and More Instantly...
Exact Sciences Corporation Company Name:
EXAS Stock Symbol:
NASDAQ Market:
Exact Sciences Corporation Website:
2024-07-11 08:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-08 08:30:00 ET To say that Exact Sciences (NASDAQ: EXAS) hasn't performed well on the stock market this year would be an understatement. Shares of the cancer-focused biotech are down by 41%. However, the healthcare company still has some fans on Wall Street. Cathie Wood ...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management w...